Description
Springer Antihypertensive Agents 1st Editon 2011 Softbound by F. Gross
1 Antihypertensive Drugs.- I. Introduction.- II. Requirements for an Antihypertensive Agent.- III. Combinations of Antihypertensive Drugs.- IV. Trends in Antihypertensive Therapy.- V. National Preferences of Treatment Schemes.- VI. Experimental Hypertension.- References.- 2 The Chemistry of Antihypertensive Agents.- I. Early Antihypertensives.- II. Adrenergic Neuronal Blockers: Guanethidine and Similar Compounds.- A. SU 4029 and Guanethidine.- B. Modification of the Guanethidine Structure.- III. Rauwolfia Alkaloids.- IV. Ganglionic Blockers.- V. Clonidine, ST 155, 2-(2, 6-dichlorophenylamino)-2-imidazoline and Analogs.- VI. The Chemistry of the Veratrum Alkaloids.- VII. Compounds Acting Directly on Vascular Smooth Muscles.- VIII. The ?-Adrenolytics (?-Adrenergic Receptor Blocking Agents).- IX. Fusaric Acid.- References.- 3 Ganglion-Blocking Drugs in Antihypertensive Therapy.- I. Introduction.- II. Characteristics of Individual Drugs, Generic, and Brand Names, Routes of Administration, and Dosages.- A. General Remarks.- B. Quaternary Ganglionic Blockers.- C. Nonquaternary Ganglionic Blockers.- III. Pharmacokinetics.- A. Methonium Compounds.- B. Mecamylamine and Pempidine.- C. Other Drugs.- IV. Mode of Action.- A. Principles of Ganglionic Transmission.- B. Drug-Induced Ganglionic Blockade.- C. Nonselective Interference with Sympathetic and Parasympathetic Transmission.- D. Effects on the Cardiovascular System.- E. Tolerance to Antihypertensive Activity.- F. Pharmacologic Effects Unrelated to Ganglionic Blockade.- V. Side-Effects.- A. General Remarks.- B. Side-Effects Due to Blockade of the Autonomic Nervous System.- C. Side-Effects Unrelated to Ganglionic Blockade.- VI. Present Role of Ganglion-Blocking Drugs.- References.- 4 The Pharmacology of Rauwolfia Alkaloids.- I. Introduction and History.- II. Absorption, Metabolism, and Distribution of Reserpine.- III. Effects of Reserpine on Levels of Catecholamines and Serotonin in Tissues.- A. Sympathetically Innervated Tissues.- B. Tissue Chromaffin Cells.- C. Adrenal Medullary Amines.- D. Peripheral Serotonin.- E. Central Nervous System.- IV. Effects of Reserpine on Uptake, Storage, Synthesis and Catabolism of Catecholamines and Serotonin.- A. Effect of Reserpine on Uptake of Amines.- B. Effect of Reserpine on Amine Storage Mechanisms.- C. Effect of Reserpine on Retention of Amines by Isolated Storage Particles.- D. Effect of Reserpine on the Synthesis of Catecholamines and Serotonin.- E. Effect of Reserpine on Catabolism of Catecholamines and Serotonin.- F. Recovery of Amine Stores After Reserpine Treatment.- V. Effect of Reserpine on Other Neurotransmitters and Auracoids.- A. Acetylcholine.- B. Histamine.- C. Tryptamine.- VI. Effects of Reserpine on Function of Peripheral Tissues.- A. Effect of Reserpine on Adrenergic Mechanisms.- B. Effects of Reserpine on Cardiac and Smooth Muscle Function.- C. Reserpine-Induced Supersensitivity.- VII. Effects of Reserpine on Central Nervous Function.- A. The Sedative and Tranquillizing Activity of Reserpine.- B. Extrapyramidal Effects of Reserpine.- C. Effect of Reserpine on Body Temperature.- D. Electrical Activity of the Brain.- E. Effects of Reserpine on Reflexes and Centrally Maintained Autonomic Nervous Tone.- F. Recovery from the Central Actions of Reserpine.- G. Interaction Between Reserpine and Other Centrally Acting Drugs.- VIII. Endocrinological, Metabolic and Structural Effects of Reserpine.- A. Effects of Reserpine on Endocrine Systems.- B. Electrolyte Metabolism.- C. Tissue Metabolism.- D. Structural Effects.- References.- 5 Adrenergic Neuron Blocking Drugs.- I. Introduction to Adrenergic Neuron Blocking Agents.- A. General Pharmacology.- B. History of Development.- C. Therapeutic Use in Hypertension.- II. Distribution of Neurin Blocking Agents in Tissues Following Their Administration to Animals and Man.- III. Interactions of Neuron